BMS-986235 + fluconazole

BMS-986235 + fluconazole is a combination of two pharmaceutical agents: BMS-986235, a selective small molecule agonist of the formyl peptide receptor 2 (FPR2), and fluconazole, a triazole antifungal agent. BMS-986235 is under investigation for its ability to promote the resolution of inflammation, particularly in the context of cardiovascular disease, by activating FPR2 signaling which enhances anti-inflammatory and tissue repair processes[2][1]. Fluconazole is a widely-used agent for the treatment of fungal infections, acting primarily through inhibition of fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, leading to disruption of ergosterol synthesis. The combination has been studied pharmacokinetically to assess how fluconazole (as a CYP inhibitor) affects the disposition and safety of BMS-986235 in healthy subjects[1]. There is no evidence that this combination is intended as a co-therapy with a unique mechanism or brand name; rather, its use is experimental, primarily for pharmacokinetic drug-drug interaction studies.